Based on efficacy and safety results from the COMBI-AD phase III trial, in 2018 the Food Drug Administration and the European Medicine Agency approved D + T for the adjuvant treatment (1-year treatment) of patients with melanoma harboring BRAF V600E or V600K mutations, as detected by an approved test, and with involvement of lymph node(s), following complete resection. The gene discussed is BRAF; the disease is melanoma.